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Conclusion: Ivabradine or atenolol can be used for heart rate
control in moderate MS patients in sinus rhythm. Ivabradine is
not superior to atenolol for controlling heart rate or exercise ca-
pacity. Left ventricular MPI was unaffected byeither of the drugs.
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Background: Percutaneous balloon mitral valvotomy (PBMV) is
well established as a safe and effective alternative to mitral ste-
nosis surgery, but only a few small studies have been reported on
the procedure. The aim of this study is to assess the safety, effi-
cacy and outcome of PBMV in Shahid Gangalal National Heart
Centre, Kathmandu, Nepal.
Methods: 262 consecutive patients who underwent balloon val-
votomy for moderate to severe mitral stenosis between July 1st
2013 to June 31st 2014 in our centre were analyzed.
Results: Among 262 patients, 74% percent of the patients were
females. Their age range was from 10years to 76years and mean
age was 33.2years. 70 (26.7%) patients were in atrial fibrillation; 6
(2%) patients were pregnant; 3 (1%) patients had Cerebrovascular
Accident; 12 (4.6%) patients underwent previous surgical or
balloon commissurotomy. The procedural success was achieved
in 84% patients. The mean left atrial pressure was reduced from
26.8 ± 8.9 mmHg to 15.6 ± 7.2 mmHg (p < 0.05).The mean mitral
valve area assessed by 2-D echocardiography increased from 0.9 ±
0.17 cm2 to 1.6 ± 0.28 cm2 (p < 0.05). 49 patients (18.7%) developed
moderate to severe mitral regurgitation. There was no mortality
related to the procedure.
Conclusion: The results of this study show that PBMV is a safe
procedure with good success rate for symptomatic mitral stenosis
with low complication rates and good clinical improvement.
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Background: Mitral stenosis is one of the most frequently
encountered cardiac abnormalities in women of child- bearing
age, accounting for nearly 90% of the cases of rheumatic heart
disease associated with pregnancy. This study was done to eval-
uate the safety and effectiveness of percutaneous balloon mitral
valvuloplasty (BMV) with severemitral stenosis during pregnancy.
Methods: A total of 30 pregnant patients were included in the study
after detailed echocardiographic evaluation. Clinical and echocar-
diographic follow-up were done by hospital visits every 3 months
after the procedure until delivery and at 6 months follow up.
Results: 14 (46.67%) patients underwent BMV during the third
trimester of pregnancy, whereas 16 (53.3%) had the procedure
performed in the second trimester. Mean gestational Age at the
time of procedure was 25.3 ± 3.93 weeks. 2 (6.6%) were in NYHA
class IV, 14 (46.7%) were in III and the remaining 14 (46.7%) of
patients were in NYHA class II.19 (63.33%) patients had a Wilkin’s
score of <8, and 11 (36.67%) had a score of >8. 29(96.3%) patients
had moderate or severe pulmonary artery hypertension, with
mean Pulmonary artery systolic pressure 68.23±23.28
mmHg.There was no maternal mortality. One patient developed
severe mitral regurgitation which underwent successful emer-
gency surgical mitral valve replacement. No patient had cere-
brovascular stroke/TIA or any vascular complications. The mean
mitral valve area was 0.85+0.16 cm2 before BMV and increased to
1.60+0.27 cm2 (p<0.0001) immediately after BMV. Peak and mean
diastolic gradients had decreased significantly 48 hours after the
procedure (p<0.001) but remained very much unchanged at 6.72
month follow-up compared with post procedure values .Two pa-
tients had an increase in mitral regurgitation by 2 grades. The
mean follow up duration was 6.72±0.56 months. 3 (11.11 %)
delivered before term.7 (25.91%) babies were having birth weight
less than 2.5 kg.
Conclusion: This study further supported the impression that
BMV was the procedure of choice to treat pregnant women with
rheumatic mitral stenosis in NYHA class II to IV. In this popula-
tion, BMV was a safe and effective procedure that resulted in
excellent immediate and intermediate-term outcomes for
mothers and their offspring.
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Background: Prosthetic heart valve thrombosis (PHVT) occurs
frequently in developing countries and causes major morbidity
andmortality. The study was done to evaluate clinical, laboratory,
and diagnostic profile of patients admitted in emergency room
with obstructive PHVT and to study efficacy, outcomes and com-
plications of thrombolytic therapy and surgical therapy for
obstructive PHVT.
Methods: A total of 82 patients with PHVT in form of acute or sub-
acute dyspnoea (<1 month) or embolic phenomena were enrolled
and confirmed with either transthoracic or trans oesophageal
echo and cine fluoroscopy and were followed up for 2 years.
Results: 29.27% patients were adequately anticoagulated on
admission while 70.73% patients were not. 97.6% cases involved
mitral while 2.4% cases involved aortic prosthesis. 94% cases had
normal left ventricular function on admission, and 91% cases had
moderate to severe pulmonary artery hypertension. Treatment
option was chosen on basis of clinical characteristics, thrombus
load, affordability, patient’s and surgeon’s preference. 67 (81.7%)
patients were treated with thrombolysis by streptokinase (88%) or
urokinase (12%), and 12(14.6%) patients undergone surgery,
3(3.6%) patients undergone surgery after failed thrombolysis. In
thrombolysis group, complete success rate was 67.16%, mortality
rate was 14.92 %, recurrence rate at 2-yr follow up was 11.94%,
while in surgery group complete success rate was 92.3%,mortality
rate was 7.7%, recurrence rate at 2-yr follow up was 23.07%.
Conclusion: Compared to surgical therapy, thrombolysis in pa-
tients with PHVT was found to have higher mortality and
complication rates but with lower recurrence rates of valve
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